How can market access teams get more from quantitative analysis? Valuate Health’s George Tenney and Terrill Paterson offer their advice in this week’s Market Access Musings. #marketaccess #quantitativeanalysis #pharma #biotech #healthcare #marketaccessmusings
Valuate Health Consultancy
Business Consulting and Services
Boston, Massachusetts 3,238 followers
Combining real world experience with advanced analytics and insights to improve market access for all.
About us
We help life sciences manufacturers and healthcare stakeholders develop and execute their value strategies to increase market access. Our consulting practice combines deep market access and reimbursement expertise with advanced analytics and insights to demonstrate value to healthcare entities. An extensive market access advisor network and innovative research methods inform a strategic approach to access and reimbursement. Our team of former payers and PBM executives, biopharma market access executives, pharmacists, data scientists, and business strategists work together to solve market access challenges. We help drug and device manufacturers evaluate reimbursement potential for new assets, design and translate health economics evidence, develop and validate product value platforms, respond to health policy changes, understand and support organizational customers, and formulate strategies to ensure products can break through market access barriers to get to patients. Because we believe people deserve access to the healthcare they need.
- Website
-
https://valuatehealth.com
External link for Valuate Health Consultancy
- Industry
- Business Consulting and Services
- Company size
- 11-50 employees
- Headquarters
- Boston, Massachusetts
- Type
- Privately Held
- Founded
- 2019
- Specialties
- Market Access Strategy, Organized Customers, Payers, Access and Reimbursement, Specialty Pharmacy, Oncology, Patient Access Programs, Health Economics Strategy, Market Research, Market Access, Pharma, Biotech, Biopharma, Rare Disease, Data Analytics, Pull-Through, Cell and Gene Therapy, and Value-Based Contracts
Locations
-
Primary
55 Franklin St
Boston, Massachusetts 02110, US
-
Princeton, NJ 08540, US
-
New York, NY 10014, US
Employees at Valuate Health Consultancy
Updates
-
In this week’s Market Access Musings, Diana Maldonado and Dionna A. share their journeys into #marketaccess, explaining how a passion for helping patients access the #healthcare they deserve, combined with a love for communication, has driven their impactful work at Entrée Health.
A Career in Market Access
Valuate Health Consultancy on LinkedIn
-
The Supreme Court made a landmark decision in the Loper Bright Enterprises v. Raimondo case, overturning the Chevron doctrine. This ruling is anticipated to impact the operations of health agencies and life sciences companies. Learn more about the future implications of this legislation and how to navigate them in our latest POV. #marketaccess #pharma #biotech #chevrondoctrine #chevrondeference
-
In this week’s issue of Market Access Musings, Mecca Scott, Emily Easley, and Mariel Hunt of Entrée Health discuss the importance of scenario planning, teamwork, and creative problem-solving to overcome the most common product launch challenges. #marketaccess #productlaunch #pharma #biotech
Launching Without Tears: Brand Team Challenges to Overcome
Valuate Health Consultancy on LinkedIn
-
In the latest issue of Market Access Musings, Ricardo Paredes from Entrée Health shares five ways to make market access strategies more inclusive and effective. #marketaccess #pharma #biotech #inclusivedesign
Five Ways to Incorporate Inclusive Design into Market Access
Valuate Health Consultancy on LinkedIn
-
In the latest issue of Market Access Musings, Elisa Remoundos of Entrée Health discusses why brand planning is the perfect opportunity to incorporate social determinants of health. #marketaccess #sdoh #pharma #biotech #healthequity
Why Brand Planning Matters for SDoH
Valuate Health Consultancy on LinkedIn
-
In the latest issue of Market Access Musings: #Asembia24 highlights from Day One, message testing for #pharma and #marketaccess, and more:
Highlights from Asembia Day 1, Message Testing for Pharma
Valuate Health Consultancy on LinkedIn
-
NEW EPISODE OF THE IDI PODCAST: Listen to Alex Goldstein Mindlin discuss message testing for #pharma and #marketaccess 👇 👇 👇 On Apple Podcasts: https://lnkd.in/eeybFVeW On Spotify: https://lnkd.in/eTX27b62
-
Valuate Health Consultancy reposted this
Day 1.5 update from #Asembia24: A lot of compelling words and phrases being used to describe the state of our healthcare system today - standouts include “chaotic change,” “uncertainty,” and.. “crisis.” At the same time there is a lot of hope that this era of tumult will give rise to incredible innovations, of which we’re already starting to see signs of through successful case studies of alternative payment and contracting models, integration of digital solutions and AI (not just a buzzword!), and execution of value-based models that are bringing the focus back to clinical outcomes (particularly evidenced by the exciting collaboration between Takeda and Optum). Looking forward to learning more about all of the above! Valuate Health Consultancy
-
Kimberly Tsai, PharmD has a report from Day 1 of #Asembia24:
Nuggets from day 1 of #Asembia2024! A lot of pulled threads from AMCP Annual, as well as some new learnings to help paint the fuller picture: Key trends to monitor in the CGT and rare disease space: - The booming category of self-insured employers (the TPA/stop-loss market is projected to grow to $800 billion by 2030) - SPs taking on restrictive management tactics (79% of SPs are reported to be using an NDA block) - Increased awareness that patient eligibility is expanding among CGT and rare disease products – rare disease is not so rare anymore - Expect new demand for more holistic care (think clinical management on top of bread-and-butter distribution and access services) to produce greater value that matches these complex patient journeys As far as the IRA goes.. While many aspects of program rollout (namely, drug price negotiation and Part D benefit redesign) remain uncertain, hard data is starting to emerge that provides some certainty to the unintended consequences we’ve been speculating about over the past year: - Most payers are planning to react to higher financial liability through mechanisms like narrower formularies (73%), increase in utilization for specialty products (93%) and negotiating for higher rebate (75%)* - While OOP smoothing via the Medicare Prescription Payment Plan will benefit many Part D beneficiaries, a significant proportion will still be left in the dust – such as the 75% of Medicare beneficiaries that have difficulty paying $2,000 to begin with, and the 77% that do not know about the OOP cap (especially problematic for an opt-in program) - As far as the Part D benefit redesign goes, manufacturers play a key role in raising awareness and proactivity among patients and providers to help drive greater participation *Presented as part of a series of data from Xcenda’s “Managed Care Network Survey,” to be officially unveiled in the coming months. Valuate Health Consultancy